LYTIX BIOPHARMA Aktie

 

Oslo, Norway, May 15, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced its results for the first quarter of 2025. With strong clinical data, a clear path to Phase III, and new international leadership onboard, Lytix is entering a defining phase. The momentum seen in Q1 2025 reflects both scientific validation and growing strategic readiness, as the company sharpens its focus on late-stage development, partnerships, and commercial execution. With solid operational progress and financial discipline, Lytix is well-positioned to deliver on its ambition to...

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its first quarter 2025 financial results on Thursday, May 15th, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights. In addition, the newly elected Chair, Eric Falcand, will be introduced and he will share some of his views on the potential of Lytix's unique technology.   Date: Thursday, May 15th, 2025 Time: 11:15 AM CET   Q&A Session: We welcome your...

Oslo, Norway, April 29, 2025 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held on April 29, 2025. All proposed resolutions on the agenda were approved.   As part of the General Meeting, a new Board of Directors was elected in line with the recommendation from the Nomination and Compensation Committee to further reinforce the company. The newly appointed board members bring broad and complementary experience across business development, oncology, fundraising, clinical development, regulatory strategy, and financial oversight. These additions will...

Oslo, 22 April 2025 – Reference is made to the notice of the Annual General Meeting in Lytix Biopharma AS (the "Company") which will be held on Tuesday 29 April 2025 at 13.00 CEST at the Company's main office at Sandakerveien 138, 0484 Oslo, Norway.    The Company's Nomination and Compensation Committee (NCC) has submitted its formal recommendation to the General Meeting. The recommendation includes proposals for the election of board members, the election of the Chair of the Board, and the remuneration of the Board of Directors and the Nomination Committee.   The recommendation...

Oslo, 10 April 2024, the Board of Directors hereby calls for the Annual General Meeting of Lytix Biopharma AS (the "Company") in Sandakerveien 130, 0484 Oslo, Norway at 13:00 Hours (CEST) on 29 April 2025.   All documents regarding the Annual General Meeting are available at the Company's website: www.lytixbiopharma.com.   For further information, please contact:   Gjest Breistein, CFO E-mail: gjest.breistein@lytixbiopharma.com Phone: +47 952 60 512   About Lytix Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel...

Oslo, Norway, April 10, 2025 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, has today published its Annual Report for 2024, which was approved by the board of directors on April 9, 2024.   2024 marked a defining year for Lytix, with significant clinical progress and strategic milestones that further de-risk and validate the company's unique immuno-oncology platform.   “2024 has been a transformative year for Lytix Biopharma,” said Øystein Rekdal, CEO of Lytix Biopharma. “We've seen continued strong clinical progress,...

Oslo, Norway, January 22, 2025 – Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, has presented clinical data on Lytix lead drug candidate, LTX-315, at the 2025 Winter Clinical Dermatology Conference held January 17-19 in Miami, Florida. The results support a potential change in the treatment paradigm for patients with basal cell carcinoma.   The three posters presented by Verrica at the conference highlighted positive clinical data from Part 2 of the Phase 2 study of LTX-315 (named VP-315 by Verrica), a novel oncolytic peptide therapy for the treatment of basal cell...

Oslo, Norway, 15 January 2025: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 17 December 2024 (the "Announcement") regarding the successful completion of a private placement (the "Private Placement") of new shares raising NOK 100 million in gross proceeds, and a retail offering of new shares raising NOK 11.3 million in gross proceeds via the PrimaryBid platform. As mentioned in the Announcement, the board of directors of the Company resolved to issue 102,568 new shares to settle part of the fee to underwriters in the...

Oslo, Norway, 7 January 2025: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 17 December 2024 regarding the successful completion of a private placement (the "Private Placement") of new shares raising NOK 100 million in gross proceeds, and a retail offering (the "PrimaryBid Offering") of new shares raising NOK 11.3 million in gross proceeds via the PrimaryBid platform. In the announcement the Company also expressed that it would consider carrying out a subsequent share offering towards existing shareholders in the Company...

Oslo, Norway, 23 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 17 December 2024 (the "Announcement") regarding the successful completion of a private placement (the "Private Placement") of new shares raising NOK 100 million in gross proceeds, and a retail offering (the "PrimaryBid Offering") of new shares raising NOK 11.3 million in gross proceeds via the PrimaryBid platform (together with the new shares in the Private Placement, the “Offer Shares”). The share capital increase relating to the Private...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.   Oslo, 17 December 2024. Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix Biopharma" or the "Company") earlier today, on 17 December 2024 regarding the successful completion of a private placement (...

Oslo, Norway, 17 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 17 December 2024, regarding the successful completion of a private placement of new shares raising NOK 100 million in gross proceeds, and a retail offering of new shares (together with the new shares in the private placement, the “Offer Shares”) raising NOK 11.3 million in gross proceeds via the PrimaryBid platform. As of this date, the Company has been informed that the following primary insiders and close associates to primary...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 17 December 2024. Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix Biopharma" or the "Company") yesterday, on 16 December 2024 regarding a contemplated private placement raising NOK 90-100...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.   Oslo, 16 December 2024 – Reference is made to the stock exchange announcement (the “Announcement”) published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today regarding, inter alia, an offering of new shares (the "Offer Shares")...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 16 December 2024, Lytix Biopharma AS ("Lytix Biopharma" or the "Company") has retained Carnegie AS and DNB Markets, a part of DNB Bank ASA, as joint bookrunners (the "Managers"), to advise on and effect a private placement of new shares...

BRIEF-Lytix Biopharma Considers Private Placement, Retail Offer Dec 16 (Reuters) - Lytix Biopharma AS LYTIX.OL : CONTEMPLATES PRIVATE PLACEMENT OF NEW SHARES RAISING NOK 90-100 MILLION IN GROSS PROCEEDS ALSO CONTEMPLATES TO EFFECT A RETAIL OFFERING OF NEW SHARES UP TO NOK EQUIVALENT OF EUR 1 MILLION VIA PRIMARYBID PLATFORM PRICE PER SHARE IN PRIVAT...

Oslo, November 21st 2024: Lytix Biopharma refers to the release made today by its licensing partner Verrica Pharmaceuticals, announcing the pricing of a USD 42 million underwritten public offering. The offering is expected to close on November 22, 2024, and the gross proceeds from the offering are expected to be approximately USD 42.0 million. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares. The full announcement can be read via this link: https://verrica.com/press_release/verrica-announces-pricing-of-42-0-million-...

Oslo, 19 November 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of tomorrow's cancer treatment, today releases its third quarter 2024 results. Lytix achieved substantial progress in its clinical pipeline, progressing towards commercialization.   “Our progress this quarter underscores Lytix's potential to deliver transformative treatments for cancer patients,” said Øystein Rekdal, CEO of Lytix Biopharma. “The positive data from our ongoing studies, especially in basal cell carcinoma and melanoma, reinforce the...

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its third quarter 2024 financial results on Tuesday, 19 November 2024.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights.   Date: Tuesday, 19 November 2024 Time: 10:30 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation....

Oslo, Norway, November 6, 2024 - Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow's cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix's lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.   “By expanding our clinical trials to early-stage melanoma patients we are adding to our robust...